Ocular Inflammation Treatment Market Value to Reach US$ 1 billion by 2026

Growing incidence rate of eye inflammations or uveitis has driven the patients toward adopting effective treatment options. In the coming years, majority of uveitis patients will be seeking ocular inflammation treatments through combination therapies, particularly due to collective effectiveness of therapeutics and prescribed drugs. Leading pharma giant Allergan Plc. has recently cleared its Ozurdex implant from FDA’s uveitis pipeline, and this new delivery system will mark a key development for combination therapies in ocular inflammation treatment. In addition to Allergan, Transparency Market Research also observes high stakes of Novartis AG, Valeant Pharmaceuticals International, Inc., Abbvie, Inc., Alimera Sciences, Inc., Eyegate Pharmaceuticals, Inc., pSivida Corporation, Pfizer, Inc., Cipla Ltd., and Akorn, Inc. in the global ocular inflammation treatment market over the coming years.

In its latest forecast study, Transparency Market Research has profiled these companies has the key stakeholders of global market for ocular inflammation treatments. Key projections from the study assess the global ocular inflammation treatment to touch a US$ 1 billion value by the end of 2026.Regulatory stance of the FDA towards clearing uveitis drugs from the pipelines is improving, and market players are being favored to introduce novel administration techniques for ocular inflammation treatments. During the period of assessment, 2017-2026, the global market for ocular inflammation treatments is pegged to expand at a CAGR of 6.9% in terms of value.

Request A Sample-


Focus on Anterior Uveitis Treatment to become Critical, Particularly in North America

The report estimates that incidence rate of uveitis in the US and Canada remains to be the highest. Over the forecast period, North America will be observed as the world’s largest ocular inflammation treatment marketplace. It is further estimated that treatment of anterior uveitis will be predominant, considering it being the world’s most common form of eye inflammation. By the end of 2026, more than US$ 530 million worth of revenues are likely to be procured from treating anterior uveitis across the globe.

Leave a Reply

Your email address will not be published. Required fields are marked *